Patent Issued for Induction and enhancement of antitumor immunity involving Sindbis virus vectors expressing immune checkpoint proteins (USPTO 12097257).

New York University has been issued a patent for the induction and enhancement of antitumor immunity using Sindbis virus vectors that express immune checkpoint proteins. The invention aims to develop new therapies to enhance anticancer treatment and elicit an immune response against tumor and cancer cells. The patent describes the use of Alphavirus vectors, such as Sindbis virus, to encode immune checkpoint proteins or fragments thereof, which can be administered to subjects with cancer or tumors. The therapeutic composition includes a fusion polypeptide that combines an immune checkpoint protein with an immunoglobulin hinge region and an immunoglobulin heavy chain constant domain. [Extracted from the article]